Mordi Ify R, Tee Aaron, Lang Chim C
Division of Molecular and Clinical Medicine, University of Dundee Dundee, UK.
Card Fail Rev. 2018 May;4(1):28-32. doi: 10.15420/cfr.2018:6:2.
There is an increasing awareness of the prevalence of iron deficiency (ID) in patients with heart failure (HF) and its contributory role in the morbidity and mortality of HF. It is important to note that many HF patients have ID without being anaemic, hence it is vital to screen for ID even in patients with haemoglobin within the normal laboratory range. This review summarises the pathophysiology and epidemiology of ID in HF before discussing the evidence for iron replacement therapy in HF patients. Finally, it discusses the ongoing large outcome trials evaluating iron replacement in HF.
人们越来越意识到心力衰竭(HF)患者中铁缺乏(ID)的普遍性及其在HF发病率和死亡率中的作用。需要注意的是,许多HF患者存在ID但未贫血,因此即使血红蛋白在实验室正常范围内的患者也有必要筛查ID。本综述总结了HF中ID的病理生理学和流行病学,然后讨论HF患者铁替代治疗的证据。最后,讨论了正在进行的评估HF中铁替代治疗的大型结局试验。